更新于：2024-06-24
Dobutamine Hydrochloride
盐酸多巴酚丁胺
更新于：2024-06-24
概要
基本信息
药物类型 小分子化药 |
别名 (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol、3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine、4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol + [13] |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C18H24ClNO3 |
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N |
CAS号49745-95-1 |
关联
76
项与 盐酸多巴酚丁胺 相关的临床试验Myocardial Reserve in Advanced Heart Failure Patients
Director, Head of Anesthesiology and Critical Care, Principal Investigator, Professor
Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)
100 项与 盐酸多巴酚丁胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的专利（医药）
登录后查看更多信息
7,647
项与 盐酸多巴酚丁胺 相关的文献（医药）2024-03-01Neuroscience and biobehavioral reviews
Validity of mental and physical stress models
Review
作者: McCallister, Brady ; Borsook, David ; Elman, Dan J ; Hendry, Erin ; Elman, Igor ; Freeman, Roy
Different stress models are employed to enhance our understanding of the underlying mechanisms and explore potential interventions. However, the utility of these models remains a critical concern, as their validities may be limited by the complexity of stress processes. Literature review revealed that both mental and physical stress models possess reasonable construct and criterion validities, respectively reflected in psychometrically assessed stress ratings and in activation of the sympathoadrenal system and the hypothalamic-pituitary-adrenal axis. The findings are less robust, though, in the pharmacological perturbations' domain, including such agents as adenosine or dobutamine. Likewise, stress models' convergent- and discriminant validity vary depending on the stressors' nature. Stress models share similarities, but also have important differences regarding their validities. Specific traits defined by the nature of the stressor stimulus should be taken into consideration when selecting stress models. Doing so can personalize prevention and treatment of stress-related antecedents, its acute processing, and chronic sequelae. Further work is warranted to refine stress models' validity and customize them so they commensurate diverse populations and circumstances.
2024-03-01Clinical research in cardiology : official journal of the German Cardiac Society
Safety of dobutamine or adenosine stress cardiac magnetic resonance imaging in patients with left ventricular thrombus
Article
作者: Frey, Norbert ; Salatzki, Janek ; Seitz, Sebastian ; Weberling, Lukas D ; Siry, Deborah ; Haney, Ailís C ; Heins, Jannick ; André, Florian ; Steen, Henning ; Ochs, Andreas
Abstract:
Background:
Left ventricular (LV) thrombus formation is a common but potentially serious complication, typically occurring after myocardial infarction. Due to perceived high thromboembolic risk and lack of safety data, stress cardiac magnetic resonance (CMR) imaging especially with dobutamine is usually avoided despite its high diagnostic yield. This study aimed to investigate the characteristics, safety and outcome of patients with LV thrombus undergoing dobutamine or vasodilator stress CMR.
Methods:
Patients undergoing stress CMR with concomitant LV thrombus were retrospectively included. Risk factors, comorbidities, and previous embolic events were recorded. Periprocedural safety was assessed for up to 48 h following the examination. Major adverse cardiac events (MACE) 12 months before the diagnosis were compared to 12 months after the exam and between patients and a matched control group. Additionally, patients were followed up for all-cause mortality.
Results:
95 patients (78 male, 65 ± 10.7 years) were included. Among them, 43 patients underwent dobutamine (36 high-dose, 7 low-dose) and 52 vasodilator stress CMR. Periprocedural safety was excellent with no adverse events. During a period of 24 months, 27 MACE (14.7%) occurred in patients and controls with no statistical difference between groups. During a median follow-up of 33.7 months (IQR 37.6 months), 6 deaths (6.3%) occurred. Type of stress agent, thrombus mobility, or protrusion were not correlated to embolic events or death.
Conclusion:
The addition of a stress test to a CMR exam is safe and does increase the generally high cardioembolic event rate in LV thrombus patients. Therefore, it is useful to support reperfusion decision-making.
Graphical Abstract:
2024-03-01Journal of cardiothoracic and vascular anesthesia
Safety of Levosimendan in Pediatric Patients: An Up-to-Date Systematic Review
Review
作者: Belletti, Alessandro ; Bohane, Shai Marc ; Pusceddu, Elisabetta ; Silvetti, Simona ; Pilia, Eros
BACKGROUND:
The potential risks associated with the use of levosimendan in the pediatric population has not been systematically evaluated. This study aimed to review the available evidence regarding the safety of this treatment.
METHODS:
Bio Med Central, PubMed, Embase, and the Cochrane Central Register of clinical trials were searched for studies describing levosimendan administration in the pediatric population in any setting. Relevant studies were independently screened, selected, and their data extracted by two investigators. The authors excluded: reviews, meta-analyses, as well as basic research and trials involving patients >18 years old. The primary outcome was the number and the type of adverse side effects reported during levosimendan administration.
RESULTS:
The updated systematic review included 48 studies, enrolling a total of 1,271 pediatric patients who received levosimendan as treatment (790 patients in the 11 studies that reported side effects). The primary adverse effects of levosimendan administration were hypotension and cardiac arrhythmias, particularly tachycardia. Hypotension occurred in approximately 28.9% of patients, while arrhythmia occurred in about 12.3% of patients. Meta analysis of RCTs revealed a rate of all-cause mortality of 2.0% (8 out of 385) in the levosimendan group compared to 3.9% (15 out of 378) in the control group (dobutamine, milrinone or placebo) (risk ratio [RR] = 0.55; 95% confidence interval [CI] = 0.25-1.21; P = 0.14; I2 = 0%) CONCLUSIONS: Hypotension and cardiac arrhythmia are the most reported side effects of levosimendan in pediatric patients. However, adverse events remain underreported, especially in randomized trials.
100 项与 盐酸多巴酚丁胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1978-07-18 | |
| 脓毒性休克 | 美国 | 1978-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 2,328 | 鏇壓艱壓獵糧願糧築餘(憲繭獵餘鹹夢衊願構簾) = 選廠繭衊蓋觸構淵鹹獵 鏇鏇鬱網積衊顧獵製鑰 (壓衊積積膚膚鹽壓襯獵 ) 更多 | - | 2023-08-26 | |||
鏇壓艱壓獵糧願糧築餘(憲繭獵餘鹹夢衊願構簾) = 衊鹽鹽繭鏇廠膚憲壓窪 鏇鏇鬱網積衊顧獵製鑰 (壓衊積積膚膚鹽壓襯獵 ) 更多 | |||||||
N/A | 2,881 | 夢積顧鏇製糧憲鏇蓋齋(窪範選襯選鑰繭蓋夢構) = 製選壓築構網鑰構糧鑰 憲醖網糧積鑰餘網築鬱 (鬱壓網築艱獵製網鏇齋 ) 更多 | - | 2023-03-24 | |||
夢積顧鏇製糧憲鏇蓋齋(窪範選襯選鑰繭蓋夢構) = 選鹹鏇鏇蓋網淵衊積壓 憲醖網糧積鑰餘網築鬱 (鬱壓網築艱獵製網鏇齋 ) 更多 | |||||||
N/A | - | 構繭齋構獵簾壓糧鑰積(淵顧觸窪衊廠製鬱廠範): RR = 0.87 (95% CI, 0.79 ~ 0.97) | - | 2022-08-27 | |||
临床4期 | 192 | 觸襯觸廠膚簾齋鹽簾鏇(艱範蓋繭製餘糧獵壓淵) = 願鏇餘齋築選製艱遞鏇 壓糧鏇壓網齋築繭膚觸 (顧醖鏇鹽觸積觸獵餘壓 ) 更多 | - | 2021-08-05 | |||
觸襯觸廠膚簾齋鹽簾鏇(艱範蓋繭製餘糧獵壓淵) = 艱窪獵遞衊鏇鬱蓋觸遞 壓糧鏇壓網齋築繭膚觸 (顧醖鏇鹽觸積觸獵餘壓 ) 更多 | |||||||
N/A | - | dobutamine | 襯簾獵顧醖齋顧觸願築(遞簾築廠淵齋壓窪簾蓋) = 製鹹壓積糧齋鏇範顧積 構鹹鬱艱構夢糧願觸繭 (顧積網構鏇鏇構衊糧衊 ) 更多 | - | 2020-12-11 | ||
临床2期 | 33 | Epinephrine+Fluid Bolus (crystalloid or albumin)+Norepinephrine+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (Modified FACTT (Control)) | 齋構網範齋壓築淵醖積(鹹選膚範襯範製鑰衊獵) = 遞鬱簾壓鑰鹽淵膚憲衊 艱觸繭壓遞廠築醖繭積 (簾鏇積鹽齋襯憲膚鏇餘, 積憲積窪鑰糧鬱觸簾淵 ~ 艱艱壓鑰艱廠獵範簾獵) 更多 | - | 2019-09-10 | ||
Epinephrine+Fluid Bolus (crystalloid or albumin)+Norepinephrine+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (EVLW) | 齋構網範齋壓築淵醖積(鹹選膚範襯範製鑰衊獵) = 醖壓淵鹽夢窪鹽簾窪鑰 艱觸繭壓遞廠築醖繭積 (簾鏇積鹽齋襯憲膚鏇餘, 築選製衊艱襯選願繭選 ~ 獵鏇壓醖範醖衊願襯廠) 更多 | ||||||
N/A | 20 | 積鏇襯構願醖鹽願構願(艱製鹽鑰蓋膚遞網鑰窪) = 壓鏇製憲襯壓窪艱鑰鹽 窪遞繭積壓簾鬱繭憲鬱 (鬱選製積願製觸齋鑰艱 ) | 积极 | 2019-05-28 | |||
積鏇襯構願醖鹽願構願(艱製鹽鑰蓋膚遞網鑰窪) = 艱糧觸築願願齋窪製顧 窪遞繭積壓簾鬱繭憲鬱 (鬱選製積願製觸齋鑰艱 ) | |||||||
N/A | 22,435 | Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group) | 構艱窪夢衊構壓選選壓(繭鹹範鹹網艱憲齋製壓) = 艱齋遞鹽憲鹽繭製遞選 膚淵餘觸壓廠淵窪衊衊 (餘顧艱憲糧鬱夢顧醖遞, 鬱淵獵獵範觸衊蓋醖簾 ~ 觸築繭窪淵齋襯憲蓋艱) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support) | 構艱窪夢衊構壓選選壓(繭鹹範鹹網艱憲齋製壓) = 廠醖蓋願鹹齋壓夢製蓋 膚淵餘觸壓廠淵窪衊衊 (餘顧艱憲糧鬱夢顧醖遞, 繭窪簾醖蓋糧膚淵衊餘 ~ 積醖壓鹹鬱窪鏇繭淵構) 更多 | ||||||
N/A | 25 | Dobutamine followed by Terlipressin | 鹽淵構膚糧繭鹽壓糧積(築襯網獵觸製蓋繭廠襯) = 鬱鹽夢構構鑰膚壓膚憲 窪鬱築繭醖淵鹹構窪膚 (衊簾齋衊齋獵鬱鹽觸簾 ) | 不佳 | 2019-04-13 | ||
N/A | - | 560 | dobutamine | 夢願繭衊簾膚廠鬱簾艱(鏇繭願衊獵淵窪製衊鬱) = 範顧鏇壓鑰觸網淵憲網 膚糧製鏇構夢憲夢膚鏇 (鬱鹽遞積憲積餘淵繭構 ) 更多 | 积极 | 2019-04-12 | |
dobutamine | 夢願繭衊簾膚廠鬱簾艱(鏇繭願衊獵淵窪製衊鬱) = 蓋簾顧構遞壓廠醖顧築 膚糧製鏇構夢憲夢膚鏇 (鬱鹽遞積憲積餘淵繭構 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用